Systemic Treatment for Adults with Synovial Sarcoma

Desar, Ingrid M.E.; Fleuren, Emmy D.G.; Graaf, Winette T.A. van der

doi:10.1007/s11864-018-0525-1

Cited by 79 publications

(82 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported metastases in 50% of those cases, while the 5-year survival is 60.5% (6,12,13). Additionally, some studies have shown a 10-year survival rate ranging between 24 and 68% (6,(12)(13)(14). The most common metastases are found in the lungs, followed by lymph nodes, bone and liver.…”

Section: Discussionmentioning

confidence: 95%

“…For cases with localized, low-risk disease treatment involves surgical resection and, in some cases, (neo)adjuvant radiotherapy (12). Previous studies reported metastases in 50% of those cases, while the 5-year survival is 60.5% (6,12,13). Additionally, some studies have shown a 10-year survival rate ranging between 24 and 68% (6,(12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

“…The most common metastases are found in the lungs, followed by lymph nodes, bone and liver. In metastatic cases, treatment is not considered curative (12).…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to other soft tissue tumors, synovial sarcomas have proven to be relatively chemo-sensitive (12). Ifosfamide, as well as ifosfamide combinations have tested active in different treatment stages.…”

Section: Discussionmentioning

confidence: 99%

“…In high-risk extremity and chest wall synovial sarcomas, neoadjuvant doxorubicin and ifosfamide has exhibited the same activity as high-dose stand-alone ifosfamide. Combination chemotherapy with doxorubicin and ifosfamide seems to improve outcome (12,15). In the first-line metastatic disease, combination with doxorubicin and ifosfamide is the preferred choice in relatively fit cases, while in the remaining patients sequential doxorubicin and ifosfamide may be administered.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Monophasic synovial sarcoma as a cause of obstructive ileus: Case report

et al. 2018

View full text Add to dashboard Cite

Synovial sarcoma is a high-grade soft tissue sarcoma, divided histologically into 3 types: Monophasic, biphasic and poorly differentiated. An extremely rare case of obstructive ileus due to monophasic synovial sarcoma in a 54-year-old male patient is reported in the present study. The patient presented to the emergency department with signs and symptoms of obstructive ileus. Computer Tomography (CT) scan showed a pelvic mass (20x17x12 cm) causing obstruction at the sigmoid colon. An exploratory laparotomy through a midline incision was performed. The described mass was unresectable as it was infiltrating major vessels. Therefore, a diverting loop descending colostomy and biopsy of the solid mass were performed. Pathological examination revealed a monophasic synovial sarcoma. The patient was referred to the Department of Oncology and started treatment with doxorubicin and ifosfamide.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

“…The most common metastases are found in the lungs, followed by lymph nodes, bone and liver. In metastatic cases, treatment is not considered curative (12).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Monophasic synovial sarcoma as a cause of obstructive ileus: Case report

et al. 2018

View full text Add to dashboard Cite

show abstract

Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma

Sasagawa,

Kumai,

Wakamatsu

et al. 2024

Cancer Innovation

View full text Add to dashboard Cite

BackgroundSynovial sarcoma (SS) is an SS18‐SSX fusion gene‐driven soft tissue sarcoma with mesenchymal characteristics, associated with a poor prognosis due to frequent metastasis to a distant organ, such as the lung. Histone deacetylase (HDAC) inhibitors (HDACis) are arising as potent molecular targeted drugs, as HDACi treatment disrupts the SS oncoprotein complex, which includes HDACs, in addition to general HDACi effects. To provide further molecular evidence for the advantages of HDACi treatment and its limitations due to drug resistance induced by the microenvironment in SS cells, we examined cellular responses to HDACi treatment in combination with two‐dimensional (2D) and 3D culture conditions.MethodsUsing several SS cell lines, biochemical and cell biological assays were performed with romidepsin, an HDAC1/2 selective inhibitor. SN38 was concomitantly used as an ameliorant drug with romidepsin treatment. Cytostasis, apoptosis induction, and MHC class I polypeptide‐related sequence A/B (MICA/B) induction were monitored to evaluate the drug efficacy. In addition to the conventional 2D culture condition, spheroid culture was adopted to evaluate the influence of cell‐mass microenvironment on chemoresistance.ResultsBy monitoring the cellular behavior with romidepsin and/or SN38 in SS cells, we observed that responsiveness is diverse in each cell line. In the apoptotic inducible cells, co‐treatment with SN38 enhanced cell death. In nonapoptotic inducible cells, cytostasis and MICA/B induction were observed, and SN38 improved MICA/B induction further. As a novel efficacy of SN38, we revealed TWIST1 suppression in SS cells. In the spheroid (3D) condition, romidepsin efficacy was severely restricted in TWIST1‐positive cells. We demonstrated that TWIST1 downregulation restored romidepsin efficacy even in spheroid form, and concomitant SN38 treatment along with romidepsin reproduced the reaction.ConclusionsThe current study demonstrated the benefits and concerns of using HDACi for SS treatment in 2D and 3D culture conditions and provided molecular evidence that concomitant treatment with SN38 can overcome drug resistance to HDACi by suppressing TWIST1 expression.

show abstract